Abbisko Cayman Limited

Equities

2256

KYG0028A1085

Biotechnology & Medical Research

Market Closed - Hong Kong S.E. 04:08:03 2024-03-28 am EDT 5-day change 1st Jan Change
2.88 HKD +0.70% Intraday chart for Abbisko Cayman Limited -4.95% -21.10%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Abbisko Cayman's Attributable Loss Narrows as Revenue, Other Gains Rise MT
Abbisko Cayman to Buy Back, Cancel Up to HK$100 Million Shares MT
Abbisko Cayman Limited commences an Equity Buyback for 70,219,935 shares, representing 10% of its issued share capital, under the authorization approved on June 14, 2023. CI
Abbisko Cayman Limited Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Abbisko Cayman Completes Dosing for Phase 1 Trials for Lung Cancer Treatment MT
Abbisko Cayman Receives $70 Million Upfront Payment for Licensing of Tumor Treatment MT
Abbisko Cayman Trustee Buys 6.1 Million Shares Under Restricted Share Scheme MT
European Medicines Agency Grants Orphan Drug Designation to Abbisko's Tumor Drug MT
Abbisko Cayman Doses First Participant in Phase 1 Trial for Anti-Tumor Treatment; Shares Fall 3% MT
Abbisko Therapeutics Co., Ltd. Completes the First Patient Dose in the Clinical Trial for Its Next-Generation CD73 Inhibitor ABSK051 CI
Abbisko Cayman Unit Gets US FDA Fast-Track Status for Tenosynovial Giant Cell Tumor Treatment MT
Abbisko Therapeutics Announces U.S. FDA Grants Fast Track Designation for CSF-1R Inhibitor Pimicotinib CI
Abbisko Cayman Doses First Patient in Phase 2 Trial for Pancreatic Cancer Treatment MT
Abbisko Therapeutics Completed the First Patient Dose in the Phase II Advanced Pancreatic Cancer Trial of CSF-1R Inhibitor Pimicotinib in China CI
China Approves Abbisko Cayman Subsidiary's Clinical Trial for Tumor Drug MT
Abbisko Therapeutics Co., Ltd. Obtains the Clinical Trial Approval from NMPA for its Next-Generation Small Molecule CD73 Inhibitor ABSK051 CI
US FDA Green Lights Abbisko Subsidiary's Phase 1 Study for Anti-Tumor Drug MT
Abbisko Therapeutics Co., Ltd. Presents Two Clinical Updates of Pimicotinib at the 2023 Connective Tissue Oncology Society Annual Meeting CI
Abbisko Cayman Presents Clinical Trial Results of Tenosynovial Giant Cell Tumor Drug at Ireland Meeting MT
Abbisko Cayman Unit to Present Data on Tenosynovial Giant Cell Tumor Drug at Conference; Shares Rise 10% MT
China Grants Clinical Study Approval for Abbisko Cayman Unit's Anti-Tumor Drug MT
Abbisko Cayman Limited to Debut Two Major Clinical Research Results At the 2023 European Society for Medical Oncology CI
Abbisko Unit Presents Two Preclinical Research Results at Cancer Treatment Conference MT
China Gives Green Light to Abbisko Cayman Arm's Phase 2 Trial for Liver Cancer Treatment MT
Abbisko Cayman Limited Announces Absk011 Hcc Combo Clinical Trial Approved by Nmpa CI
Chart Abbisko Cayman Limited
More charts
Abbisko Cayman Ltd is a China-based clinical-stage biopharmaceutical company. The Company is dedicated to the discovery and development of innovative and differentiated small molecule oncology therapies. The Company owns two Core Product Candidates, ABSK011 and ABSK091, and 12 other pipeline product candidates. ABSK011 is a potent and highly selective small molecule inhibitor of fibroblast growth factor receptor 4 (FGFR4). ABSK091 is a molecularly targeted product candidate and a highly potent and selective inhibitor of FGFR subtypes 1, 2 and 3. The Company's products are primarily being developed for hepatocellular carcinoma (HCC), urothelial cancer (UC) and gastric cancer (GC).
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
2.66 CNY
Average target price
7.572 CNY
Spread / Average Target
+184.69%
Consensus
  1. Stock
  2. Equities
  3. Stock Abbisko Cayman Limited - Hong Kong S.E.
  4. News Abbisko Cayman Limited
  5. Abbisko Cayman : Raises $207 Million in Hong Kong IPO Ahead of Wednesday Debut